Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Many More COVID-19 Vaccine Changes Ahead, ACIP Expecting Fewer Public Meetings

Executive Summary

CDC’s Advisory Committee on Immunization Practices wants a more feasible and sustainable meeting schedule in 2022, which would reduce transparency.

You may also be interested in...



Janssen COVID-19 Vaccine Adds Another Thrombotic Warning

US FDA adds a warning about immune thrombocytopenia, joining the risk of Thrombosis with Thrombocytopenia Syndrome.

Novavax Readies COVID-19 Vaccine Request For EUA, But How Much Longer Will The Door Be Open?

Availability of emergency authorization route in US depends upon lack of 'adequate, approved and available alternatives,' but as more vaccines make their way through the BLA process sponsors may find the EUA door slowly closing.

ACIP Upgrades Child Vaccine Booster Recommendation To ‘Should’

Not only should children age 12 to 15 get a booster, but 16- and 17-year-olds who previously 'may' get a booster, now also 'should' get one, the CDC advisory committee said.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel